Neuralink’s vision-restoring brain implant, Blindsight, gains FDA’s “breakthrough device” designation, accelerating its development toward restoring vision for the blind.
By yourNEWS Media Newsroom
Elon Musk’s brain-chip startup Neuralink announced on Tuesday that its experimental vision-restoring implant, Blindsight, has been granted “breakthrough device” designation by the U.S. Food and Drug Administration (FDA). This designation is intended to fast-track the development and review process for medical devices aimed at treating life-threatening or serious conditions.
Blindsight, Neuralink’s cutting-edge brain implant, is designed to restore vision to those who have lost both their eyes and optic nerve. Musk elaborated on the breakthrough via a post on X (formerly Twitter), stating that the device “will enable even those who have lost both eyes and their optic nerve to see.”
While the FDA and Neuralink have not provided further details on when the device may advance to human trials, the designation signifies a critical step toward its realization. The FDA’s breakthrough device designation typically accelerates the timeline for approval, allowing for closer collaboration between the company and the agency in the interest of bringing potentially life-changing devices to market sooner.
Neuralink, founded in 2016 by Musk and a team of engineers, is developing brain-chip interfaces that could revolutionize treatments for disabled patients, enabling them to regain mobility, communicate, and even restore lost senses such as sight. The chip processes and transmits neural signals, which can then be sent to external devices, such as computers or phones, facilitating new ways for individuals to interact with the world.
Blindsight is one of several innovations in Neuralink’s portfolio. The company is also working on a brain implant designed to help paralyzed individuals use digital devices purely by thought, potentially offering life-altering functionality to those with spinal cord injuries. Neuralink has already begun testing this implant in humans, enrolling three patients for trials that are expected to continue for several years.
Earlier in 2024, the second patient involved in the trials successfully had the device implanted and has been using it to play video games and even design 3D objects using only their mind.
While it remains unclear when Blindsight will enter human trials, the FDA’s breakthrough designation marks a significant milestone for Neuralink’s mission to push the boundaries of neural interface technology, bringing hope to millions affected by severe disabilities or sensory loss.